Edition:
India

Fortress Biotech Inc (FBIO.OQ)

FBIO.OQ on NASDAQ Stock Exchange Capital Market

4.20USD
20 Apr 2018
Change (% chg)

$-0.10 (-2.33%)
Prev Close
$4.30
Open
$4.27
Day's High
$4.31
Day's Low
$4.14
Volume
24,827
Avg. Vol
41,523
52-wk High
$5.53
52-wk Low
$3.13

Latest Key Developments (Source: Significant Developments)

Mustang Bio Reports Q4 Financial Results
Friday, 30 Mar 2018 

March 29 (Reuters) - Fortress Biotech Inc ::MUSTANG BIO REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.FORTRESS BIOTECH - ‍AS OF DEC 31, 2017, MUSTANG'S CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AND RESTRICTED CASH TOTALED $61.5 MILLION.  Full Article

Avenue Says Dosed First Patient in Phase 3 Safety Trial of IV Tramadol
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 3 SAFETY TRIAL OF INTRAVENOUS TRAMADOL FOR THE MANAGEMENT OF POSTOPERATIVE PAIN.AVENUE THERAPEUTICS INC - COMPANY EXPECTS TO INITIATE A SECOND PHASE 3 TRIAL IN PATIENTS FOLLOWING ABDOMINOPLASTY SURGERY IN Q3 OF 2018.AVENUE THERAPEUTICS- EVALUATING IV TRAMADOL IN PHASE 3 TRIAL IN PATIENTS FOLLOWING BUNIONECTOMY SURGERY, EXPECTS TO REPORT TOPLINE DATA IN Q2,2018.  Full Article

Mustang Bio's Mb-102 Car T Therapy Achieves Complete Response In Phase 1 Clinical Trial
Tuesday, 12 Dec 2017 

Dec 11 (Reuters) - Fortress Biotech Inc ::MUSTANG BIO'S MB-102 (CD123 CAR) CAR T THERAPY ACHIEVES COMPLETE RESPONSE IN ACUTE MYELOID LEUKEMIA AND BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM IN PHASE 1 CLINICAL TRIAL.MUSTANG BIO - INVESTIGATORS FOUND INFUSIONS OF MB-102 ARE SAFE AND WELL TOLERATED.MUSTANG BIO - CAR T THERAPY IS SAFE, WELL TOLERATED.  Full Article

Mustang Bio reports Q3 loss per share of $0.27
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Mustang Bio::Mustang Bio reports third quarter 2017 financial results and recent corporate highlights.Q3 loss per share $0.27.  Full Article

Fortress Biotech posts Q3 loss per share $0.67
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Fortress Biotech Inc :Fortress Biotech reports third quarter 2017 financial results and recent corporate highlights.Q3 loss per share $0.67.Q3 revenue $46.9 million versus $1.0 million.  Full Article

Fortress Biotech announces pricing of series a preferred stock offering
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Fortress Biotech Inc :Fortress Biotech Inc announces pricing of series a preferred stock offering.Fortress Biotech Inc - ‍priced offering of one million shares of its 9.375 pct series a cumulative redeemable perpetual preferred stock at $25.00 per share​.  Full Article

Fortress Biotech proposes public offering of Series A preferred stock
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Fortress Biotech Inc :Fortress Biotech announces proposed public offering of Series A preferred stock.  Full Article

Mustang Bio enters lease agreement for production of Car T therapies
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Fortress Biotech Inc :Entered lease agreement for manufacturing facility to support clinical development, commercialization of co's Car T product candidates​.Facility is expected to be operational for production of personalized Car T therapies in 2018​.Has entered into a lease agreement with UMASS Medicine Science Park in Worcester, Massachusetts​.  Full Article

Mustang Bio announces $12.8 mln grant to fund Phase 1 trial of CAR T therapy MB-101 in malignant glioma
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Fortress Biotech Inc ::Mustang Bio announces $12.8 million grant to fund Phase 1 trial of CAR T therapy MB-101 in malignant glioma.  Full Article

Fortress Biotech Q4 revenue $16.5 mln
Friday, 17 Mar 2017 

Fortress Biotech Inc : Fortress Biotech reports financial results for the fourth quarter and full year ended december 31, 2016 .Q4 revenue $16.5 million.  Full Article

BRIEF-Mustang Bio Reports Q4 Financial Results

* MUSTANG BIO REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS